Login / Signup

Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.

Sophia FrentzasAnna Rachelle Austria MislangCharlotte LemechAdnan NagrialCraig UnderhillWenjing WangZhongmin Maxwell WangBaiyong LiYu XiaJermaine I G Coward
Published in: Journal for immunotherapy of cancer (2024)
NCT04047290.
Keyphrases
  • endothelial cells
  • vascular endothelial growth factor
  • open label
  • clinical trial